

NORTHWEST  
**GYNECOLOGICAL**  
CANCER SYMPOSIUM 2019

SEPT 25, 2019 · SEATTLE, WA

*Bringing together gynecological researchers from  
Washington, Oregon & British Columbia*



RIVKINCENTER



## PROGRAM

- 8:00am – 8:30am Check-in & Poster Set-up
- 8:30am – 8:40am **Opening Remarks by Kiran Dhillon, PhD**, Rivkin Center

### SESSION I: DETECTION AND PREVENTION

- Moderator** **Rosana Risques, PhD** (2017 Pape Family Pilot Study Award; 2019 Rivkin Bridge Funding Award)
- 8:40am – 8:55am *Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian cancer*  
**Rosana Risques, PhD**, University of Washington
- 8:55am – 9:10am *The effect of OCP use on the incidence of pre-cancerous p53 lesions in fallopian tube fimbria*  
**Kendall Greening, MSc**, BC Cancer Research Centre
- 9:10am – 9:25am *Clinical tissue proteomics identifies new mesonephric carcinoma biomarkers*  
**Evan Gibbard**, University of British Columbia
- 9:25am – 9:40am *Ethnic disparity in detection of ovarian malignancy*  
**Charles Dunton, MD**, ASPIRA Labs
- 9:40am – 10:10am **Coffee Break**

### SESSION II: CANCER MECHANISMS

- Moderator** **Bo Yu, MD** (2017 Cookie Laughlin Bridge Funding Award)
- 10:10am – 10:25am *Modelling initiation events of low-grade serous ovarian cancers with organoid cultures and single cell sequencing*  
**Joyce Zhang**, BC Cancer Research Centre
- 10:25am – 10:40am *Targeted next-generation sequencing identifies mutations in epigenetic regulators in a large cohort of adult-type granulosa cell tumors*  
**Jessica Pilsworth**, University of British Columbia
- 10:40am – 10:55am *Single cell RNA sequencing of normal endometrial organoids reveals prognostic markers in gynecologic tumors*  
**Dawn Cochrane, PhD**, BC Cancer Research Centre
- 10:55am – 11:00am **Keynote Introduction by Mark Carey, MD**
- 11:00am – 12:00pm **Keynote Address**  
*Defining the trajectory of ovarian cancer from early tubal precursors*  
**Ronny Drapkin, MD/PhD**, University of Pennsylvania
- 12:00pm – 1:00pm **Lunch** (provided)
- 12:00pm – 1:00pm **Trainee Lunch with Keynote Speaker**



### SESSION III: MANAGEMENT AND RESOURCES

- Moderator**                      **Robyn Andersen, PhD** (2017 Pilot Study Award)
- 1:00pm – 1:15pm      *Piloting a meditation intervention for ovarian cancer survivors to change Heart Rate Variability (HRV)*  
**Robyn Andersen, PhD**, Fred Hutchinson Cancer Research Center
- 1:15pm – 1:30pm      *Quality improvement assessment of a standardized multidisciplinary approach to prescribing PARP inhibitors*  
**Amy Indorf, PharmD**, University of Washington/Seattle Cancer Care Alliance
- 1:30pm – 1:45pm      *Improving findability of gynecological biospecimens and associated data through the Cascadia Data Discovery Initiative*  
**Brenda Kostecky, PhD**, Cascadia Data Alliance at Fred Hutch
- 1:45pm – 2:10pm      **Poster Presentation Lightning Round**
- 2:10pm – 2:40pm      **Coffee Break**

### SESSION IV: THERAPEUTICS

- Moderator**                      **Andre Lieber, MD/PhD** (2010 Pilot Study Award; 2016 Lester and Bernice Smith Challenge Grant)
- 2:40pm – 2:55pm      *Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models*  
**Andre Lieber, MD/PhD**, University of Washington
- 2:55pm – 3:10pm      *Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors*  
**Kristin Anderson, PhD**, Fred Hutchinson Cancer Research Center
- 3:10pm – 3:25pm      *The immune and tumor metabolic ecosystem in human ovarian cancer*  
**Julian Lum, PhD**, BC Cancer Research Centre
- 3:25pm – 3:40pm      *Inflammatory response in endometrial carcinoma is associated with tumor phenotype and host exposures in the Nurses' Health Study*  
**T. Rinda Soong, MD/PhD**, University of Washington
- 3:40pm – 3:45pm      **Closing Remarks by Nora Disis, MD**

### SESSION V: POSTER SESSION

- 3:45pm – 5:00pm      **Poster Session**
- 5:00pm – 6:30pm      **RECEPTION**



## POSTERS

*A CLIA certified functional precision medicine assay, the PARIS© test, to predict drug response for ovarian cancer*

**Carla Grandori, MD/PhD**, SEngine Precision Medicine

*Single-cell sequencing to investigate the cellular origins of endometrium-derived ovarian carcinomas*

**Germain C. Ho**, BC Cancer Research Centre

*CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines*

**Joshua Hoenisch**, University of British Columbia

*Potential for vitamin D in the prevention of ovarian cancer in women with BRCA1 mutations*

**Sonali Joshi, PhD**, Oregon Health and Science University

*Single cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor*

**Marilyne Labrie, PhD**, Oregon Health and Science University

*Targeting FANCD2 increases chemosensitivity of ovarian cancer cells*

**Tanja Pejovic, MD/PhD**, Knight Cancer Institute / Oregon Health and Science University

*Selective killing of SMARCA4-deficient ovarian cancer by mitochondria respiration inhibitors*

**Yemin Wang, PhD**, BC Cancer Research Centre

*Microbiome profiling of fallopian tubes*

**Bo Yu, MD**, University of Washington

## PLANNING COMMITTEE

**Mark Carey, MD**, University of British Columbia

**Kiran Dhillon, PhD**, Rivkin Center for Ovarian Cancer

**Nora Disis, MD**, University of Washington / Fred Hutch

**Jackie Lang, PhD**, Rivkin Center for Ovarian Cancer

**Gordon Mills, MD/PhD**, Oregon Health and Science University

## SPONSORS

TBA